M
Matinas BioPharma Holdings, Inc.
MTNBCIK 0001582554NYSENon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-10.35M
Total Assets
$7.21M
Equity
$4.83M
Shares Out
6.41M
Op. Cash Flow
$-7.01M
Business
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company developing therapies using its proprietary lipid nanocrystal (LNC) platform delivery technology. Its lead candidate, MAT2203, is an oral formulation of amphotericin B for treating invasive fungal infections such as cryptococcal meningitis and invasive aspergillosis. The company has paused internal development and is seeking partnerships or capital to advance MAT2203 toward Phase 3 clinical trials, while maintaining its IND and intellectual property. Matinas operates in the United States and operates under exclusive licensing agreements with Rutgers University for its LNC Platform technology.
Summary from 10-K filed 2026-03-31
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 85,000 | 11 | 14 | 17 | 15 | |
| General and administrative | 7 | 9 | 10 | 11 | 10 | |
| Impairment charges of goodwill and other intangible assets | — | 2 | — | — | — | |
| Impairment charges of other assets | — | 2 | — | — | — | |
| Total costs and expenses | 7 | 25 | 25 | 28 | 25 | |
| Loss from operations | −7 | −25 | −24 | −25 | −25 | |
| Change in fair value of warrant liability | −3 | — | — | — | — | |
| Gain on sale of assets | 37,000 | — | — | — | — | |
| Other (expenses)/income, net | −261,000 | 262,000 | 340,000 | 102,000 | 124,000 | |
| Loss before tax | −10 | −24 | −23 | — | — | |
| Income tax benefit | — | 80,000 | — | — | — | |
| Net loss | −10 | −24 | −23 | −21 | −23 | |
| Deemed dividend relating to warrant exchange | −618,000 | — | — | — | — | |
| Net loss attributable to common shareholders | −11 | −24 | — | −21 | −24 | |
| Net loss per share - basic | −2 | −4.98 | −5.28 | −0.1 | −0.11 | |
| Net loss per share - diluted | −2 | −4.98 | −5.28 | −0.1 | — | |
| Weighted average common shares outstanding - basic | 5 | 5 | 4 | 217 | 210 | |
| Weighted average common shares outstanding - diluted | 5 | 5 | 4 | 217 | — | |
| Unrealized gain on securities available-for-sale | — | 221,000 | 603,000 | −679,000 | −374,000 | |
| Other comprehensive gain, net of tax | — | 221,000 | 603,000 | −679,000 | −374,000 | |
| Comprehensive loss | −10 | −24 | −22 | −22 | −24 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2025 2025-11-30 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 4 | — | 7 | 5 | 7 | |
| Restricted cash security deposit | 50,000 | — | 50,000 | 50,000 | 50,000 | |
| Prepaid expenses and other current assets | 26,000 | — | 691,000 | 2 | 6 | |
| Total current assets | 4 | — | 8 | 16 | 35 | |
| Leasehold improvements and equipment - net | 138,000 | — | 468,000 | 2 | 2 | |
| Operating lease right-of-use assets - net | 531,000 | 207,000 | 2 | 3 | 4 | |
| Finance lease right-of-use assets - net | 4,000 | — | 8,000 | 21,000 | 30,000 | |
| In-process research and development | 2 | — | 2 | 3 | 3 | |
| Restricted cash - security deposit | 200,000 | — | 200,000 | 200,000 | 200,000 | |
| Total non-current assets | 3 | — | 5 | 10 | 10 | |
| Total assets | 7 | — | 13 | 25 | 45 | |
| Accounts payable | 315,000 | — | 95,000 | 514,000 | 618,000 | |
| Accrued expenses and other liabilities | 452,000 | — | 2 | 1 | — | |
| Operating lease liabilities - current | 694,000 | — | 761,000 | 656,000 | 562,000 | |
| Financing lease liabilities - current | 2,000 | — | 5,000 | 5,000 | 7,000 | |
| Total current liabilities | 1 | — | 3 | 3 | 4 | |
| Deferred tax liability | 257,000 | — | 257,000 | 341,000 | 341,000 | |
| Operating lease liabilities - net of current portion | 653,000 | — | 2 | 3 | 4 | |
| Financing lease liabilities - net of current portion | 5,000 | — | 12,000 | 18,000 | 22,000 | |
| Total non-current liabilities | 915,000 | — | 2 | 3 | 4 | |
| Total liabilities | 2 | — | 5 | 6 | 8 | |
| Series C Convertible preferred stock, stated value $1,000 per share, par value $0.0001 per share, 10,000,000 shares authorized at December 31, 2025 and 2024; 3,155 and 0 issued and outstanding as of December 31, 2025 and 2024, respectively. Liquidation preference of $3,155,000 as of December 31, 2025. | — | — | — | — | — | |
| Common stock par value $0.0001 per share, 500,000,000 and 250,000,000 shares authorized at December 31, 2025 and 2024, respectively; 6,406,191 and 5,086,985 issued and outstanding as of December 31, 2025 and 2024, respectively | 1,000 | — | 1,000 | — | 22,000 | |
| Additional paid-in capital | 216 | — | 207 | — | — | |
| Accumulated deficit | −211 | — | −200 | −176 | −153 | |
| Total stockholders equity | 5 | — | 8 | 19 | 37 | |
| Total liabilities and stockholders equity | 7 | — | 13 | 25 | 45 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 32,000 | 365,000 | 385,000 | 337,000 | 244,000 | |
| Net gain on disposal of assets | −37,000 | — | — | — | — | |
| Stock-based compensation expense | 1 | 3 | 5 | 5 | 4 | |
| Loss on operating lease right-of-use assets modification | 241,000 | — | — | — | — | |
| Amortization of operating lease right-of-use assets | 420,000 | 602,000 | 548,000 | 542,000 | 501,000 | |
| Amortization of finance lease right-of-use assets | 4,000 | 5,000 | 8,000 | 19,000 | 36,000 | |
| Amortization of bond premium | — | −17,000 | 107,000 | 211,000 | 250,000 | |
| Income tax benefit | — | −84,000 | — | — | — | |
| Prepaid expenses and other current assets | 665,000 | 587,000 | 4 | −4 | 1 | |
| Accounts payable | 220,000 | −419,000 | −103,000 | −321,000 | 588,000 | |
| Accrued expenses and other liabilities | −1 | 356,000 | −2 | 249,000 | 57,000 | |
| Operating lease liabilities | −1 | −655,000 | −562,000 | −520,000 | −460,000 | |
| Net cash used in operating activities | −7 | −16 | −15 | −19 | −15 | |
| Proceeds from sale of assets | 335,000 | — | — | — | — | |
| Purchases of marketable debt securities | — | −8 | — | −9 | −23 | |
| Proceeds from sales of marketable debt securities | — | 18 | 13 | 15 | 40 | |
| Net cash provided by investing activities | 335,000 | 9 | 13 | 5 | 17 | |
| Gross proceeds from private placement of preferred stock and common stock warrants | 3 | — | — | — | — | |
| Transaction costs paid pursuant to private placement | −29,000 | — | — | — | — | |
| Net proceeds from exercise of warrants | 129,000 | — | — | — | — | |
| Net proceeds from public offerings of common stock and warrants | — | 9 | — | — | — | |
| Payments of capital lease liability principal | −9,000 | −5,000 | −7,000 | −20,000 | −30,000 | |
| Net cash provided by financing activities | 3 | 9 | −7,000 | 79,000 | 7 | |
| Net (decrease)/increase in cash, cash equivalents and restricted cash | −3 | 2 | −2 | −14 | 9 | |
| Reclassification of warrants from liability to equity | 6 | — | — | — | — | |
| Unrealized gain on marketable debt securities | — | 221,000 | 603,000 | −679,000 | −374,000 | |
| Exchange of warrants for shares of common stock | 618,000 | — | — | — | — | |
| Reduction of right-of-use assets and lease liabilities on lease termination | 488,000 | — | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is Matinas BioPharma Holdings, Inc.'s CIK number?
Matinas BioPharma Holdings, Inc.'s SEC CIK number is 0001582554 (1582554). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Matinas BioPharma Holdings, Inc.'s SEC filings?
All of Matinas BioPharma Holdings, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.